VEGFA and angiosarcoma: Paclitaxel (50–100 nM but not 10 nM) significantly reduced MS1 VEGF angiosarcoma cell number to ~64.8 ± 7.2% (50 nM) and ~44.23 ± 8.4% (100 nM) of control, respectively (Fig. 3g).